117 related articles for article (PubMed ID: 23757939)
1. Acyloxymethyl esters of isophosphoramide mustard as new anticancer prodrugs.
Cytarska J; Misiura K; Filip-Psurska B; Wietrzyk J
Acta Pol Pharm; 2013; 70(3):481-7. PubMed ID: 23757939
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells.
Roth T; Tang W; Eisenbrand G
Anticancer Drug Des; 1995 Dec; 10(8):655-66. PubMed ID: 8595124
[TBL] [Abstract][Full Text] [Related]
3. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
4. Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).
Misiura K; Szymanowicz D; Kuśnierczyk H; Wietrzyk J; Opolski A
Acta Biochim Pol; 2002; 49(1):169-76. PubMed ID: 12136937
[TBL] [Abstract][Full Text] [Related]
5. Chemically stable, lipophilic prodrugs of phosphoramide mustard as potential anticancer agents.
Kwon CH; Moon KY; Baturay N; Shirota FN
J Med Chem; 1991 Feb; 34(2):588-92. PubMed ID: 1995881
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
[TBL] [Abstract][Full Text] [Related]
7. Phenylalanyl-aminocyclophosphamides as model prodrugs for proteolytic activation: synthesis, stability, and stereochemical requirements for enzymatic cleavage.
Jiang Y; Hu L
Bioorg Med Chem Lett; 2007 Jan; 17(2):517-21. PubMed ID: 17064897
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen.
Wu X; Hu L
Bioorg Med Chem; 2016 Jun; 24(12):2697-706. PubMed ID: 27156193
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase.
Hernick M; Flader C; Borch RF
J Med Chem; 2002 Aug; 45(16):3540-8. PubMed ID: 12139465
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of sulfonylethyl-containing phosphotriesters of 3'-azido-3'-deoxythymidine as anticancer prodrugs.
Wang J; Wang YJ; Chen ZS; Kwon CH
Bioorg Med Chem; 2014 Nov; 22(21):5747-56. PubMed ID: 25440502
[TBL] [Abstract][Full Text] [Related]
12. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
13. Phosphate prodrugs of isophosphoramide mustard.
Misiura K; Szymanowicz D; Wietrzyk J; Opolski A
Acta Pol Pharm; 2003; 60(2):109-12. PubMed ID: 13678316
[TBL] [Abstract][Full Text] [Related]
14. An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation.
Adidala R; Devalapally H; Srivari C; Devarakonda R K; Akkinepally RR
Drug Dev Ind Pharm; 2012 Sep; 38(9):1047-53. PubMed ID: 22185667
[TBL] [Abstract][Full Text] [Related]
15. Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.
Skarbek C; Lesueur LL; Chapuis H; Deroussent A; Pioche Durieu C; Daville A; Caron J; Rivard M; Martens T; Bertrand JR; Le Cam E; Vassal G; Couvreur P; Desmaele D; Paci A
J Med Chem; 2015 Jan; 58(2):705-17. PubMed ID: 25494842
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of 1-aldofosfamide-perhydrothiazines.
Zimmermann J; Bauer HH; Hohorst HJ; Voelcker G
Arzneimittelforschung; 2000 Sep; 50(9):843-7. PubMed ID: 11050703
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
18. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
[TBL] [Abstract][Full Text] [Related]
19. Aldophosphamide acetal diacetate and structural analogues: synthesis and cytotoxicity studies.
Wang YQ; Farquhar D
J Med Chem; 1991 Jan; 34(1):197-203. PubMed ID: 1992116
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide.
Struck RF; Schmid SM; Waud WR
Cancer Chemother Pharmacol; 1994; 34(3):191-6. PubMed ID: 8004750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
